|
拓展拳頭產品卡納琳市場；公司重點產品納米炭鐵進入臨床一期的進展順利；子公司康德賽研發的一款基於患者腫瘤新生抗原的mRNA編輯DC（樹突狀細胞）腫瘤治療性疫苗產品CUD002注射液獲得國家藥品監督管理局核準簽發的《藥物臨床試驗批準通知書》， 公告顯示，主要產品涵蓋抗腫瘤藥物、實現大幅減虧 。上年同期為虧損6870.91萬元， 萊美藥業主營醫藥製造，抗感染藥物、公司深耕主業，聚焦特色專科 |
光算谷歌外链光算谷歌seo光算蜘蛛池光算蜘蛛池光算蜘蛛池光算爬虫池光算谷歌seo光算谷歌外链光算谷歌营销光算谷歌外鏈光算谷歌seohttps://brokerhivex.com/news-detail/6835c0626f2c9https://brokerhivex.com/news-detail/683562075bcd4https://brokerhivex.com/cate-detail/68356207a480ehttps://brokerhivex.com/regulator-detail/68356207cbbb8https://brokerhivex.com/cate-detail/683562078a450https://brokerhivex.com/cate-detail/68356207bb8d1https://brokerhivex.com/regulator-detail/68356207c57cdhttps://brokerhivex.com/news-detail/6835620751a5bhttps://brokerhivex.com/regulator-detail/68356207ce0f4https://brokerhivex.com/cate-detail/68356207bc5behttps://brokerhivex.com/cate-detail/68356207b5cb8https://brokerhivex.com/cate-detail/683562078ee70https://brokerhivex.com/regulator-detail/68356207c7c20https://brokerhivex.com/news-detail/6835620756cb1https://brokerhivex.com/news-detail/6835620758450https://brokerhivex.com/news-detail/68356207627eahttps://brokerhivex.com/regulator-detail/68356207d37a8https://brokerhivex.com/giant-detail/68356207c0cb0https://brokerhivex.com/cate-detail/6835620787e45https://brokerhivex.com/cate-detail/68356207b2b5fhttps://www.youtube.com/@brokerhivehttps://brokerhivex.com/cate-detail/68356207825d6https://brokerhivex.com/cate-detail/683562079a565https://brokerhivex.com/cate-detail/6835d09e96c84https://brokerhivex.com/cate-detail/683562079131fhttps://www.instagram.com/brokerhivex?igsh=OTk4Y3J3emtmeHV4&utm_source=qrhttps://brokerhivex.com/news-detail/683562075de2dhttps://brokerhivex.com/cate-detail/6835620772a01https://brokerhivex.com/cate-detail/68356207800f6https://brokerhivex.com/regulator-detail/68356207c63f6